Team Building in the White Mountains
July 27, 2021
July 27, 2021 – Biocytogen Boston Corporation held a team-building retreat at the Grand View Mountain Resort in New Hampshire last week. The event, propelled by the extensive recent growth of the USA Team, offered the opportunity for employees to engage with new colleagues across all departments, participate in outdoor recreational activities, and enjoy the […]
Biocytogen/Eucure Biopharma’s CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA
July 7, 2021
BOSTON and BEIJING, July 6, 2021 –Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing antibody drugs with independent intellectual property rights, announced that the U.S. Food and Drug Administration (FDA) has approved two phase II clinical trials for YH001 (anti-CTLA-4) and YH003 (anti-CD40) in the United States. A phase II, non-randomized, multi-center […]
Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars
June 22, 2021
BEIJING and BOSTON, June 22, 2021- Biocytogen, an international biotechnology company focused on antibody drug research and development using innovative genetically engineered animal models, today announced the successful completion of a new round of financing totaling tens of millions of dollars. The financing was jointly completed by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. […]
Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting
June 1, 2021
BEIJING and BOSTON, June 1, 2021 /PRNewswire/ — Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held from June 4th to 8th. The first trial (poster #2580; NCT04481009) is designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor efficacy of YH003 (an anti-CD40 monoclonal antibody (mAb)) […]
Biocytogen Best Research Paper Award commends typhoid toxin and potential peptide therapy research
May 27, 2021
Boston, May 27, 2021, adapted from Cornell Chronicle, Graduate students and postdoctoral researchers in the Department of Microbiology and Immunology from Cornell University faced stiff competition for this year’s Biocytogen Best Research Paper Award. Their work in infectious disease and host immune responses has been recognized in peer-reviewed journals, and faculty members faced the difficult […]
Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences’ Anti-PD-1
March 23, 2021
BOSTON and BEIJING, March 22, 2021 /PRNewswire/ — Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences’ anti-PD-1 monoclonal antibody, Toripalimab Injection (TUOYI®), has demonstrated encouraging anti-tumor activity in a dose-escalation Phase I clinical trial in Australia. The study was designed to evaluate the safety, tolerability, pharmacokinetics, […]
Biocytogen announces acquisition of a third Beacon Optofluidic system
March 5, 2021
BOSTON, Feb. 25, 2021 /PRNewswire/ — Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument, developed by Berkeley Lights, will support the expansion of Biocytogen’s antibody discovery service platform in the greater Boston area for collaborations across the globe.Founded on its successful gene editing platform, Biocytogen […]
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences’ Toripalimab
February 10, 2021
BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ — Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences’ anti-PD-1 antibody Toripalimab (TUOYI®), demonstrated encouraging anti-tumor activity in an ongoing Phase I/II clinical trial in Australia. The trial is a multicenter, open label study, with an initial multiple-dose-escalation […]
Biocytogen and LiberoThera Enter into Strategic Collaboration Agreement
February 1, 2021
Beijing, China and Tokyo, Japan, February 1st, 2021 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and LiberoThera Co.,Ltd (“LiberoThera”) announced today that they have entered into an agreement for strategic collaboration on fully human therapeutic GPCR antibody development incorporating Biocytogen’s world-class antibody discovery expertise based on its fully human antibody RenMab™ mouse platform with LiberoThera’s state-of-the-art […]
Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China
January 29, 2021
BOSTON and BEIJING, Jan. 26, 2021 /PRNewswire/ — Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for a Phase I clinical trial in China to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of its anti-CTLA4 monoclonal antibody (YH001) in patients with solid tumors. In May 2020, Eucure Biopharma initiated a first-in-human Phase I dose-escalation trial of YH001 in advanced solid […]
